Novo Nordisk Inc. today announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes. Products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir®, Novolin®, NovoLog® and NovoLog® Mix 70/30. Novo Nordisk is also reducing the list price of unbranded biologics to match the lowered price of each respective branded insulin. These changes will go into effect on January 1, 2024.
Novo Nordisk recognizes that some patients find it difficult to pay
for healthcare, including insulin. As such, the Company remains
committed to reducing the burden of out-of-pocket costs, helping
transform the complex pricing system, and fostering better pricing
predictability. Novo Nordisk continually reviews and revises our
offerings as well as works with diverse stakeholders to create
solutions for differing patient needs.
“We have been working to develop a sustainable path forward that
balances patient affordability, market dynamics, and evolving policy
changes,” said Steve Albers, senior vice president, Market Access
& Public Affairs at Novo Nordisk, Inc. “Novo Nordisk remains
committed to ensuring patients living with diabetes can afford our
insulins, a responsibility we take seriously.”
The following changes to the wholesale acquisition cost (WAC), also known as the list price, will take effect on January 1, 2024:
Additionally, Novo Nordisk has a variety of long-standing U.S. affordability offerings available to eligible people living with diabetes, including:
Novo Nordisk will continue to work with a diverse group of
stakeholders to understand emerging patient needs. People living with
diabetes are encouraged to access and learn more about these
affordability programs at NovoCare.com.
Please visit mynovoinsulin.com for more important information about Novo Nordisk Inc. insulins.
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity and rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in seven states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, and Twitter.
Allison Schneider (US) +1 732 513 4875, firstname.lastname@example.org
Mark Joseph Root (US) +1 848 213 3219 email@example.com
Questions from non-U.S. media should be directed to GlobalMedia@novonordisk.com.